Cargando…
Autoimmune disorders but not heparin are associated with cell-free fetal DNA test failure
BACKGROUND: Recent studies have suggested a possible association between heparin treatment at the time of cell-free DNA (cfDNA) testing and a non-reportable result. However, these studies lack of proper methodology and had a low level of proof to firmly incriminate heparin. Our objective was to inve...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276207/ https://www.ncbi.nlm.nih.gov/pubmed/30509296 http://dx.doi.org/10.1186/s12967-018-1705-2 |
_version_ | 1783377968557457408 |
---|---|
author | Dabi, Yohann Guterman, Sarah Jani, Jacques C. Letourneau, Alexandra Demain, Adèle Kleinfinger, Pascale Lohmann, Laurence Costa, Jean-Marc Benachi, Alexandra |
author_facet | Dabi, Yohann Guterman, Sarah Jani, Jacques C. Letourneau, Alexandra Demain, Adèle Kleinfinger, Pascale Lohmann, Laurence Costa, Jean-Marc Benachi, Alexandra |
author_sort | Dabi, Yohann |
collection | PubMed |
description | BACKGROUND: Recent studies have suggested a possible association between heparin treatment at the time of cell-free DNA (cfDNA) testing and a non-reportable result. However, these studies lack of proper methodology and had a low level of proof to firmly incriminate heparin. Our objective was to investigate further the relationship between heparin treatment and cfDNA test results. METHODS: Two complementary approaches were used for the demonstration. First, we conducted a retrospective analysis of a cohort of patients with a singleton pregnancy, screened for aneuploidies by using cfDNA, but with a non-reportable cfDNA result. We included patients between 2013 and 2016 including the patients from the DEPOSA study as controls. CfDNA testing was performed by massive parallel sequencing by using a whole-genome approach. A multiple logistic regression was used to account for the influence of the variables included. Second, we performed in vitro experiments on mimic samples containing increased concentrations of heparin. RESULTS: Of 9867 singleton pregnancies tested during the inclusion period, 58 (0.59%) had a non-reportable result and were compared to 295 control patients. Fifteen (25.9%) and 20 (6.8%) patients were treated with heparin in the group with a non-reportable cfDNA result and with a successful assay, respectively. In multivariable analysis, an increased calculated risk at the first-trimester combined screening (OR 28.8 CI 9.76–85.15, p < 0.001), maternal weight (OR 1.03, CI 1.01–1.06, p = 0.01), and the presence of an autoimmune disease (OR 10.38, CI 1.62–66.53, p = 0.01) were the only characteristics associated with a non-reportable result. In vitro experiments showed that heparin had no impact on fetal fraction measurement or the final result, no matter what the dose tested. CONCLUSIONS: Treatment by heparin had no impact on cfDNA screening test for aneuploidies, while the presence of an autoimmune disorder is an independent predictor of a non-reportable result. |
format | Online Article Text |
id | pubmed-6276207 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-62762072018-12-06 Autoimmune disorders but not heparin are associated with cell-free fetal DNA test failure Dabi, Yohann Guterman, Sarah Jani, Jacques C. Letourneau, Alexandra Demain, Adèle Kleinfinger, Pascale Lohmann, Laurence Costa, Jean-Marc Benachi, Alexandra J Transl Med Research BACKGROUND: Recent studies have suggested a possible association between heparin treatment at the time of cell-free DNA (cfDNA) testing and a non-reportable result. However, these studies lack of proper methodology and had a low level of proof to firmly incriminate heparin. Our objective was to investigate further the relationship between heparin treatment and cfDNA test results. METHODS: Two complementary approaches were used for the demonstration. First, we conducted a retrospective analysis of a cohort of patients with a singleton pregnancy, screened for aneuploidies by using cfDNA, but with a non-reportable cfDNA result. We included patients between 2013 and 2016 including the patients from the DEPOSA study as controls. CfDNA testing was performed by massive parallel sequencing by using a whole-genome approach. A multiple logistic regression was used to account for the influence of the variables included. Second, we performed in vitro experiments on mimic samples containing increased concentrations of heparin. RESULTS: Of 9867 singleton pregnancies tested during the inclusion period, 58 (0.59%) had a non-reportable result and were compared to 295 control patients. Fifteen (25.9%) and 20 (6.8%) patients were treated with heparin in the group with a non-reportable cfDNA result and with a successful assay, respectively. In multivariable analysis, an increased calculated risk at the first-trimester combined screening (OR 28.8 CI 9.76–85.15, p < 0.001), maternal weight (OR 1.03, CI 1.01–1.06, p = 0.01), and the presence of an autoimmune disease (OR 10.38, CI 1.62–66.53, p = 0.01) were the only characteristics associated with a non-reportable result. In vitro experiments showed that heparin had no impact on fetal fraction measurement or the final result, no matter what the dose tested. CONCLUSIONS: Treatment by heparin had no impact on cfDNA screening test for aneuploidies, while the presence of an autoimmune disorder is an independent predictor of a non-reportable result. BioMed Central 2018-12-03 /pmc/articles/PMC6276207/ /pubmed/30509296 http://dx.doi.org/10.1186/s12967-018-1705-2 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Dabi, Yohann Guterman, Sarah Jani, Jacques C. Letourneau, Alexandra Demain, Adèle Kleinfinger, Pascale Lohmann, Laurence Costa, Jean-Marc Benachi, Alexandra Autoimmune disorders but not heparin are associated with cell-free fetal DNA test failure |
title | Autoimmune disorders but not heparin are associated with cell-free fetal DNA test failure |
title_full | Autoimmune disorders but not heparin are associated with cell-free fetal DNA test failure |
title_fullStr | Autoimmune disorders but not heparin are associated with cell-free fetal DNA test failure |
title_full_unstemmed | Autoimmune disorders but not heparin are associated with cell-free fetal DNA test failure |
title_short | Autoimmune disorders but not heparin are associated with cell-free fetal DNA test failure |
title_sort | autoimmune disorders but not heparin are associated with cell-free fetal dna test failure |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276207/ https://www.ncbi.nlm.nih.gov/pubmed/30509296 http://dx.doi.org/10.1186/s12967-018-1705-2 |
work_keys_str_mv | AT dabiyohann autoimmunedisordersbutnotheparinareassociatedwithcellfreefetaldnatestfailure AT gutermansarah autoimmunedisordersbutnotheparinareassociatedwithcellfreefetaldnatestfailure AT janijacquesc autoimmunedisordersbutnotheparinareassociatedwithcellfreefetaldnatestfailure AT letourneaualexandra autoimmunedisordersbutnotheparinareassociatedwithcellfreefetaldnatestfailure AT demainadele autoimmunedisordersbutnotheparinareassociatedwithcellfreefetaldnatestfailure AT kleinfingerpascale autoimmunedisordersbutnotheparinareassociatedwithcellfreefetaldnatestfailure AT lohmannlaurence autoimmunedisordersbutnotheparinareassociatedwithcellfreefetaldnatestfailure AT costajeanmarc autoimmunedisordersbutnotheparinareassociatedwithcellfreefetaldnatestfailure AT benachialexandra autoimmunedisordersbutnotheparinareassociatedwithcellfreefetaldnatestfailure |